Anti-HER2 Therapy Beyond Second-Line for HER2- Positive Metastatic Breast Cancer: A Short Review and Recommendations for Several Clinical Scenarios from a Spanish Expert Panel

Publisher： Karger

E-ISSN： 1661-3805|11|2|133-138

ISSN： 1661-3791

Source： Breast Care, Vol.11, Iss.2, 2016-02, pp. : 133-138

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Therapy Standards in HER2-Positive Breast Cancer

By  

Breast Care, Vol. 11, Iss. 2, 2016-04 ,pp. : 148-150

Karger

Access to resources Recommend Favorite

Treatment with Combinations of the Anti-HER2 Antibody Trastuzumab and Capecitabine in Advanced Metastatic Breast Cancer Patients – a Pilot Study

By  

Breast Care, Vol. 2, Iss. 4, 2007-08 ,pp. : 227-233

Karger

Access to resources Recommend Favorite

HER2-Orientated Therapy in Early and Metastatic Breast Cancer

By  

Breast Care, Vol. 11, Iss. 6, 2016-12 ,pp. : 392-397

Karger

Access to resources Recommend Favorite

Systemic Treatment Options for HER2-Positive Breast Cancer Patients with Brain Metastases beyond Trastuzumab: A Literature Review

By  

Breast Care, Vol. 12, Iss. 3, 2017-06 ,pp. : 168-171

Karger

Access to resources Recommend Favorite

HER2-Positive Neuroendocrine Breast Cancer: Case Report and Review of Literature

By  

Breast Care, Vol. 11, Iss. 6, 2016-12 ,pp. : 424-426

Karger

Access to resources Recommend Favorite